Dr. Ann Murchison, M.D
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,360 | 9 | 82.6% |
| Travel and Lodging | $1,412 | 4 | 12.5% |
| Food and Beverage | $564.78 | 6 | 5.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $7,292 | 7 | $0 (2019) |
| Merck Sharp & Dohme LLC | $3,760 | 8 | $0 (2024) |
| Genentech USA, Inc. | $202.41 | 1 | $0 (2019) |
| Merz Pharmaceuticals, LLC | $35.84 | 1 | $0 (2021) |
| Horizon Therapeutics plc | $27.91 | 1 | $0 (2021) |
| Allergan, Inc. | $18.27 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $750.00 | 1 | Merck Sharp & Dohme LLC ($750.00) |
| 2022 | $750.00 | 2 | Merck Sharp & Dohme LLC ($750.00) |
| 2021 | $582.02 | 4 | Merck Sharp & Dohme Corporation ($500.00) |
| 2020 | $500.00 | 1 | Merck Sharp & Dohme Corporation ($500.00) |
| 2019 | $7,914 | 9 | Genentech, Inc. ($7,292) |
| 2018 | $840.00 | 2 | Merck Sharp & Dohme Corporation ($840.00) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 05/23/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 03/02/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 07/28/2021 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $35.84 | General |
| Category: Musculoskeletal | ||||||
| 07/20/2021 | Allergan, Inc. | RESTASIS MULTIDOSE (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: DRY EYE | ||||||
| 06/11/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 05/11/2021 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $27.91 | General |
| Category: TEPEZZA | ||||||
| 05/27/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 10/30/2019 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $202.41 | General |
| Category: Immunology | ||||||
| 07/27/2019 | Genentech, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $194.68 | General |
| Category: Immunology | ||||||
| 07/26/2019 | Genentech, Inc. | Actemra (Biological) | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| Category: Immunology | ||||||
| 07/26/2019 | Genentech, Inc. | Actemra (Biological) | Travel and Lodging | In-kind items and services | $634.34 | General |
| Category: Immunology | ||||||
| 07/26/2019 | Genentech, Inc. | Actemra (Biological) | Travel and Lodging | Cash or cash equivalent | $568.65 | General |
| Category: Immunology | ||||||
| 07/26/2019 | Genentech, Inc. | Actemra (Biological) | Travel and Lodging | In-kind items and services | $174.48 | General |
| Category: Immunology | ||||||
| 07/26/2019 | Genentech, Inc. | Actemra (Biological) | Food and Beverage | Cash or cash equivalent | $85.67 | General |
| Category: Immunology | ||||||
| 07/26/2019 | Genentech, Inc. | Actemra (Biological) | Travel and Lodging | Cash or cash equivalent | $34.20 | General |
| Category: Immunology | ||||||
| 04/10/2019 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $420.00 | General |
| 03/22/2018 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $420.00 | General |
| 02/16/2018 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $420.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 7 | 287 | 298 | $57,910 | $27,393 |
| 2020 | 7 | 343 | 351 | $66,825 | $29,546 |
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 119 | 120 | $27,000 | $11,275 | 41.8% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2021 | 59 | 59 | $15,635 | $8,584 | 54.9% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2021 | 35 | 35 | $4,375 | $2,160 | 49.4% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 26 | 30 | $4,350 | $2,117 | 48.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 18 | 18 | $2,700 | $1,521 | 56.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 11 | 15 | $1,850 | $1,195 | 64.6% |
| 76512 | Ultrasound of eye disease, growth, or structure | Facility | 2021 | 19 | 21 | $2,000 | $540.76 | 27.0% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2020 | 160 | 161 | $36,225 | $14,844 | 41.0% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2020 | 46 | 46 | $12,190 | $6,686 | 54.9% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2020 | 41 | 44 | $6,360 | $2,899 | 45.6% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2020 | 42 | 42 | $5,250 | $2,029 | 38.7% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 20 | 20 | $3,000 | $1,672 | 55.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 13 | 13 | $1,300 | $734.58 | 56.5% |
| 76512 | Ultrasound of eye disease, growth, or structure | Facility | 2020 | 21 | 25 | $2,500 | $680.00 | 27.2% |
About Dr. Ann Murchison, M.D
Dr. Ann Murchison, M.D is a Ophthalmic Plastic and Reconstructive Surgery healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942311485.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ann Murchison, M.D has received a total of $11,336 in payments from pharmaceutical and medical device companies, with $750.00 received in 2024. These payments were reported across 19 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($9,360).
As a Medicare-enrolled provider, Murchison has provided services to 630 Medicare beneficiaries, totaling 649 services with total Medicare billing of $56,939. Data is available for 2 years (2020–2021), covering 14 distinct procedure/service records.
Practice Information
- Specialty Ophthalmic Plastic and Reconstructive Surgery
- Other Specialties Ophthalmology
- Location Philadelphia, PA
- Active Since 08/31/2006
- Last Updated 05/10/2017
- Taxonomy Code 207WX0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1942311485
Products in Payments
- Actemra (Biological) $7,494
- Xeomin (Biological) $35.84
- TEPEZZA (Drug) $27.91
- RESTASIS MULTIDOSE (Drug) $18.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.